Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT07204236
EARLY_PHASE1
Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological Conversion
Sponsor: Grand Theravac Life Sciences (Nanjing) Co., Ltd.
View on ClinicalTrials.gov
Summary
The objective of this study is to assess the immunogenicity and safety of TVAX-008 injection in antiviral untreated/untreated chronic hepatitis B patients with HBsAg≤20 IU/mL, or HBsAg negative and no seroconversion through an investigator-initiated clinical study.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-01-18
Completion Date
2026-03-01
Last Updated
2025-10-02
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
TVAX-008
TVAX-008
Locations (1)
Shandong Province Public Health Clinical Center
Jinan, Shandong, China